Methods of treating cutaneous ulcers and grafts using agonist antibodies to IL-23 receptor
View Patent ↗Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.
1. A method of improving healing of a cutaneous ulcer or cutaneous graft comprising administering to a subject an effective amount of an agonist antibody, or antigen binding fragment thereof, that specifically binds to human IL-23 receptor (hIL-23R), wherein contact of the agonist antibody to a cell expressing hIL-23R and hIL-12Rβ1 results in an increase in proliferation of the cell.
2. The method of claim 1 , wherein the agonist antibody comprises a complex of:
a) a light chain comprising the mature amino acid sequence of SEQ ID NO:10; and
b) a heavy chain comprising the mature amino acid sequence of SEQ ID NO:12.
3. The method of claim 2 wherein the agonist antibody, or antigen binding fragment thereof, comprises two light chains and two heavy chains.
4. The method of claim 1 wherein the agonist antibody, or antigen binding fragment thereof, is
a monoclonal antibody, or antigen binding fragment thereof.
5. The method of claim 4 wherein the agonist antibody, or antigen binding fragment thereof, is an Fab, Fv, or F(ab′)2 fragment.
6. The method of claim 1 wherein the agonist antibody, or antigen binding fragment thereof, is a humanized antibody, or antigen binding fragment thereof.
7. The method of claim 6 wherein the agonist antibody, or antigen binding fragment thereof, is an Fab, Fv, or F(ab′)2 fragment.
8. The method of claim 1 wherein the agonist antibody, or antigen binding fragment thereof, is an Fab, Fv, or F(ab′)2 fragment.
9. The method of claim 1 wherein the agonist antibody, or antigen binding fragment thereof, comprises:
a) a light chain comprising hypervariable regions consisting of:
i) a first CDR consisting of residues 46-56 of SEQ ID NO: 10;
ii) a second CDR consisting of residues 72-78 of SEQ ID NO: 10; and
iii) a third CDR consisting of residues 111-119 of SEQ ID NO: 10;
and
b) a heavy chain comprising hypervariable regions consisting of:
i) a first CDR consisting of residues 45-54 of SEQ ID NO: 12;
ii) a second CDR consisting of residues 69-87 of SEQ ID NO: 12; and
iii) a third CDR consisting of residues 118-126 of SEQ ID NO: 12.